Apilimod mesylate
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Apilimod mesylate
- Molecular weight
- 550.63
- Structure (SMILES)
- COc1ccc(-c2nc(S(C)(=O)=O)[nH]c2-c2ccc(OC)cc2)cc1.CS(=O)(=O)O.CS(=O)(=O)O
- apilimod bis mesylate
- Apilimod bis-mesylate
- apilimod dimesylate
- Apilimod dimesylate
- Apilimod dimesylate [WHO-DD]
- apilimod dimesylate capsule
- Apilimod Dimesylate Capsule
- apilimod dimesylate who dd
- apilimod mesilate
- Apilimod mesilate
- apilimod mesylate
- Apilimod mesylate
- APILIMOD MESYLATE [USAN]
- apilimod mesylate usan
- benzaldehyde 3 methyl 2 6 4 morpholinyl 2 2 2 pyridinyl ethoxy 4 pyrimidinyl hydrazone methanesulfonate 1 2
- benzaldehyde 3 methyl 2 6 4 morpholinyl 2 2 2 pyridinyl ethoxy 4 pyrimidinyl hydrazone methanesulphonate 1 2
- benzaldehyde 3 methyl 6 4 morpholinyl 2 2 2 pyridinyl ethoxy 4 pyrimidinyl hydrazone dimethanesulfonate
- benzaldehyde 3 methyl 6 4 morpholinyl 2 2 2 pyridinyl ethoxy 4 pyrimidinyl hydrazone dimethanesulphonate
- benzaldehyde 3 methyl 6 4 morpholinyl 2 2 2 pyridinyl ethoxy 4 pyrimidinyl hydrazone mesilate
- benzaldehyde 3 methyl 6 4 morpholinyl 2 2 2 pyridinyl ethoxy 4 pyrimidinyl hydrazone mesylate
- BENZALDEHYDE, 3-METHYL-, (6-(4-MORPHOLINYL)-2-(2-(2-PYRIDINYL)ETHOXY)-4-PYRIMIDINYL)HYDRAZONE MESILATE
- BENZALDEHYDE, 3-METHYL-, (6-(4-MORPHOLINYL)-2-(2-(2-PYRIDINYL)ETHOXY)-4-PYRIMIDINYL)HYDRAZONE MESYLATE
- BENZALDEHYDE, 3-METHYL-, (6-(4-MORPHOLINYL)-2-(2-(2-PYRIDINYL)ETHOXY)-4-PYRIMIDINYL)HYDRAZONE, DIMETHANESULFONATE
- BENZALDEHYDE, 3-METHYL-, (6-(4-MORPHOLINYL)-2-(2-(2-PYRIDINYL)ETHOXY)-4-PYRIMIDINYL)HYDRAZONE, DIMETHANESULPHONATE
- BENZALDEHYDE, 3-METHYL-, 2-(6-(4-MORPHOLINYL)-2-(2-(2-PYRIDINYL)ETHOXY)-4-PYRIMIDINYL)HYDRAZONE METHANESULFONATE (1:2)
And 13 more, listed on the interactive page.
- CAS registry numbers
- 870087-36-8
- ChEMBL ID
- CHEMBL6067997
- InChIKey
- QAFWUMUPMXXFFK-UHFFFAOYSA-N
- FDA ingredient codes (UNII)
- 5G3P5OK11S
- 11527330
- 177644613
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -imod
Mechanisms of action
- Mechanism
- 1-phosphatidylinositol 3-phosphate 5-kinase inhibitor
- Action type
- Inhibitor
- Target
- 1-phosphatidylinositol 3-phosphate 5-kinase
- Protein identifier
- Q9Y2I7
Open Targets mechanisms
- Mechanism
- 1-phosphatidylinositol 3-phosphate 5-kinase inhibitor
- Action type
- Inhibitor
- Target
- 1-phosphatidylinositol 3-phosphate 5-kinase
- Condition
- Crohn Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000384
- Subject identifier
- D003424
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition identifier
- EFO_0000384
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005952
- Highest recorded phase
- 2
- Condition identifier
- HP_0004386
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004976
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005011
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0015517
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018908
- Highest recorded phase
- 2
- NCT00138840
- NCT00234741
- NCT00642629
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 1
- Polar surface area
- 81.28
- Calculated partition coefficient (ALogP)
- 3.16
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 35
- Molecular formula
- C20H26N2O10S3
- Monoisotopic mass
- 550.07495855
- Natural product
- No
Related records
Trials (25)
- A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
- A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers
- A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer
- A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
- A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
- A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
- A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes
- A Study of LAM-002A for the Prevention of Progression of COVID-19
- A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults
- A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
- A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
- Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
- Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
- Mid-and Long-term Efficacy of Ergot Alkaloids in the Treatment of Salivation in Patients With Parkinson's Disease.
- Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors
- STA-5326 in Crohn's Disease Patients
- STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency
- Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant
- Study of PWT33597 Mesylate in Subjects With Advanced Malignancies
In development for (3)
- Crohn disease Phase 2
- Non-Hodgkin lymphoma Phase 2
- Rheumatoid arthritis Phase 2
Targets (1)
- PIKFYVE 1-phosphatidylinositol 3-phosphate 5-kinase inhibitor